20190604 - Nova Biomedical Canada Ltd. Industry Workshop - IWT111 - 0730-0830 |
Nova Biomedical Canada Ltd. Industry Workshop
Session Title:
Management of dysglycemia in critically ill patients - recent FDA clearances & consequences
Presenters:
Wei Qiu, Nova Biomedical
Objectives:
At the conclusion of this session, participants will be able to:
1. Review FDA historical background for BGMS
2. Review evolution of StatStrip labelling changes and clearances
3. Review study design for arterial and venous claim
4. Review FDA Advisory Panel presentation
5. Review study design for capillary claim
6. Review FDA device classifications
7. Summarize implications for use
Presenters:
Wei Qiu, Nova Biomedical
Objectives:
At the conclusion of this session, participants will be able to:
1. Review FDA historical background for BGMS
2. Review evolution of StatStrip labelling changes and clearances
3. Review study design for arterial and venous claim
4. Review FDA Advisory Panel presentation
5. Review study design for capillary claim
6. Review FDA device classifications
7. Summarize implications for use